Diabetic eye disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• VEGF 19
• GLP-1 1
• NRF2 0
• NLRP3 1
• AMPK 0
• AKT 0
• SGLT2 1
• HIF-1 0
• PPAR 0
• PI3K 0
• mTOR 0
• STAT3 0
• MAPK 0
• STING 0
• SIRT1 0
• ERK 0
• GPX4 0
• IL-1 0
• TLR4 0
• YAP 0
• ACE2 0
• CTNNB1 0
• HMGB1 0
• IL-6 1
• MMP-9 0
• TNF 0
• TP53 0
• ANGPTL3 0
• BDNF 0
• CXCR4 0
• FTO 0
• GIP 0
• HDAC 0
• IL-17 0
• JAK 0
• MEK 0
• PDGFR 0
• PINK1 0
• APOE 0
• AQP4 0
• BAP1 0
• BCL-2 0
• CCR5 0
• CD40 0
• CDK4/6 0
• CDKN2A 0
• COX-2 0
• DPP-4 0
• EGFR 0
• FAK 0
• G6PD 0
• IL-15 0
• IL-4 0
• JNK 0
• MDM2 0
• METTL3 0
• MYC 0
• NMDA 0
• RPGR 0
• TDP-43 0

14 of 14+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R01

  Retinal Cell Loss in Diabetic Retinopathy

  Wayne State University· Detroit, United States· US$387,500 awarded in fiscal year 2026· until May 2030

• NIH NEI · R43

  PRMT5 Inhibitors as a Novel Therapy for Anti-VEGF-Sensitive and -Resistant Neovascular Age-Related Macular Degeneration

  Eqon Pharmaceuticals, Llc· Carmel, United States· US$233,247 awarded in fiscal year 2026· until Aug 2028

• NIH NEI · R01

  Mobile Strategy for Improving Eye Health of Kidney Patients Treated with Dialysis (SIGHT)

  University of Washington· Seattle, United States· US$1,383,760 awarded in fiscal year 2026· until Aug 2031

• NIH NEI · U01

  RURAL Eye Health Study

  Southern California Eye Institute· Los Angeles, United States· US$1,089,223 awarded in fiscal year 2026· until May 2031

• NIH NEI · R01

  Mechanisms of Sodium-Driven Glial Dysfunction in Hypertensive Retinopathy

  Meharry Medical College· Nashville, United States· US$654,161 awarded in fiscal year 2026· until Jun 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Tailored lipid nanoparticles for iontophoretic ocular drug delivery. (ODiN)

  Universita Degli Studi di Parma· Parma, Italy· EU contribution €193,643· until Jan 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Exploring Natural Immunity in Retinal Neovascular Disease (NK InSight)

  The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin· Dublin, Ireland· EU contribution €1,999,681· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

7 of 228 running projects, newest first. Listed amounts together: US$132.7m + €2.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

  NCT06398080· Regeneron Pharmaceuticals· Updated 25 Nov 2024

  “Sponsor Decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

  NCT06985706· Belfast Health and Social Care Trust· Source

• Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and Safety

  NCT07481500· Jakkrit Juhong· Source

• A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

  NCT04503551· Hoffmann-La Roche· Source

• Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery

  NCT07301775· Ahmad Zeeshan Jamil· Source

• Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

  NCT04278417· Novartis Pharmaceuticals· Source

• Effect of Video Viewing on Intravitreal Injection Experience

  NCT07002372· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME.

  NCT06846073· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 2
• Mendelian Randomization Analysis 27
• CRISPR-Cas Systems 4
• Gene Expression Profiling 34
• Sequence Analysis, RNA 3
• Exome Sequencing 2
• Proteomics 30
• Metabolomics 15
• Mass Spectrometry 2
• Flow Cytometry 5
• Immunohistochemistry 13
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 4
• Machine Learning 49
• Deep Learning 73
• Cohort Studies 47
• Genome-Wide Association Study 23

• An Exploratory Single-Cell Analysis Identifies Candidate Shared Molecular Features in Proliferative Diabetic Retinopathy and Parkinson's Disease.

  Genes (Basel), Aug 2026

• Single-cell transcriptomic analysis of ferroptosis-associated cell populations in the progression of diabetic retinopathy.

  Int Ophthalmol, Aug 2026

• Single-cell analysis of the human retina reveals stage-linked microglial states and neural-immune circuit rewiring in diabetic retinopathy.

  Genomics, Aug 2026

• Single-cell transcriptomic integrated with machine learning reveals human retinal cell-specific biomarkers in diabetic retinopathy.

  Hum Mol Genet, Jul 2026

• Human single-cell atlas of proliferative diabetic retinopathy reveals a SOX15-overexpressing stromal population driving retinal fibrosis through the endothelin-1 -EDNRB axis.

  J Transl Med, Jul 2026

• Integrating Proteome-Wide Association Studies and Single-Cell Transcriptomics Identifies GSTT2B as a Causal Mediator and Prioritizes COL4A1 in Diabetic Retinopathy.

  Int J Mol Sci, Jul 2026

• Endothelial dysfunction in human diabetic vascular complications: translating single-cell transcriptomics into therapeutic opportunities.

  Mol Med, Jul 2026

• COL1A1 and SERPINE1 as Potential Therapeutic Targets in Diabetic Retinopathy: A Study Incorporating RNA Transcriptomics, Single-Cell RNA Sequencing, and Proteomics.

  Hum Mutat, Jul 2026

• Single cell transcriptomic analysis reveals pathogenic cell heterogeneity and candidate inflammatory-associated markers in STZ-induced diabetic mouse retina.

  Front Immunol, Apr 2026

• Integrative analysis of transcriptomics, single-cell RNA sequencing, and GraphBAN identifies de novo lipogenesis-associated genes and their potential roles in diabetic retinopathy.

  Front Immunol, Apr 2026

See which targets of this disease your abstract mentions, and go to the people working on them.